Company News

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen Approvals in the United States and Europe are anticipated in 2020 DUBLIN, IRELAND – [...]

2023-04-05T09:50:32+01:00September 9th, 2019|All News, Company News, Previous Sectors|

Relievant Announces Publication of Positive Results from Multi-Center Study of the Intracept® Procedure in Real-world Setting for Patients with Chronic Low Back Pain

MINNEAPOLIS – August 27, 2019 – Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the publication of significant and clinically-meaningful outcomes from a prospective, open-label, single-arm, multi-center study in the European Spine Journal. This study follows previous publication of [...]

2023-04-06T10:28:15+01:00August 27th, 2019|All News, Company News|

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure

V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure CAESAREA, Israel, Aug. 15, 2019 — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough [...]

2023-04-03T11:08:50+01:00August 19th, 2019|All News, Company News|

Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar

Zurich-Schlieren, Switzerland, August 06, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) of its strategic partner Allergan for abicipar, a [...]

2023-04-05T10:32:29+01:00August 7th, 2019|All News, Company News, Previous Sectors|

CeQur appoints Bradley Paddock Chief Executive Officer

Medical Device Veteran Has 23-Year Record of Successful Commercial and Organizational Leadership MARLBOROUGH, Mass., June 5, 2019 — CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million [...]

2023-04-12T12:40:58+01:00June 6th, 2019|All News, Blog, Company News|

Boston Scientific Announces Agreement to Acquire Vertiflex, Inc.

Boston Scientific Announces Agreement to Acquire Vertiflex, Inc. Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies. Vertiflex has raised approximately $160 million in funding from investors including Endeavour Vision, NEA and H.I.G. BioVentures. MARLBOROUGH, Mass., May 9, 2019 / — Boston Scientific (NYSE: [...]

2023-04-03T13:10:30+01:00May 9th, 2019|All News, Company News|

Nuvaira receives French innovation funding for Nuvaira Airflow-3 pivotal trial

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies. Novel program provides reimbursement for TLD therapy in France MINNEAPOLIS, April 28, 2018 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, has received acceptance from the Haute Autorité de Santé (HAS, the [...]

2023-07-24T16:48:36+01:00May 6th, 2019|All News, Company News|

Relievant announces publication of SMART trial 24-month results

Intracept® Procedure Demonstrates Durable Results at 24 Months. MINNEAPOLIS – April 24, 2019 – Relievant Medsystems, a privately-held medical device company developing minimally-invasive solutions for chronic low back pain (CLBP), today announced the publication of 24-month results from the SMART trial in the International Journal of Spine Surgery. A [...]

2023-04-03T16:04:54+01:00April 28th, 2019|All News, Company News|

SOPHiA GENETICS achieves CE-IVD milestone

for its Solid Tumor Solution for accurate cancer detection. Lausanne, SWITZERLAND – 11 April 2019: SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today the CE-IVD marking of its Solid Tumor Solution (STS), a new step in the fight against cancer. This standardized molecular diagnostic application precisely detects and [...]

2023-04-03T14:48:22+01:00April 11th, 2019|All News, Company News|

William T. Abraham, Md Joins V-wave as Chief Medical Officer

William T. Abraham, Md Joins V-wave as Chief Medical Officer CAESAREA, Israel, March 11, 2019 – V-Wave Ltd., an early stage medtech company, developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that renowned heart failure cardiologist, William [...]

2023-03-29T08:50:51+01:00March 11th, 2019|All News, Company News|
Go to Top